financetom
Business
financetom
/
Business
/
Form 8.3 - Spectris plc
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3 - Spectris plc
Sep 15, 2025 6:38 PM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

 

Millennium International Management LP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

 

Spectris plc ( SEPJF )

If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

 

12th September 2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

 

No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

5p ordinary (GB0003308607)

 

 

 

Interests

 

Short positions

 

Number

 

%

 

Number

 

%

(1) Relevant securities owned and/or controlled:

 

-

 

-

 

-

 

-

(2) Cash-settled derivatives:

 

 

2,267,061

 

2.281%

 

2,853

 

0.003%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

-

 

-

 

-

-

-

 

TOTAL:

 

2,267,061

 

2.281%

 

2,853

 

0.003%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

 

 

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

 

Purchase/sale

 

 

Number of securities

 

Price per unit (GBP)

 

 

 

 

 

 

 

(b) Cash-settled derivative transactions

Class of relevant security

 

Product description

e.g. CFD

 

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 

Number of reference securities

 

Price per unit

 

GB0003308607

 

Equity Swap

 

Reducing a long Position

 

35

 

40.86 GBP

GB0003308607

 

Equity Swap

 

Increasing a short Position

 

2

 

40.88 GBP

GB0003308607

 

Equity Swap

 

Increasing a short Position

 

287

 

40.89 GBP

GB0003308607

 

Equity Swap

 

Increasing a short Position

 

77

 

40.89 GBP

GB0003308607

 

Equity Swap

 

Reducing a long Position

 

150

 

40.88 GBP

GB0003308607

 

Equity Swap

 

Increasing a long Position

 

3

 

40.88 GBP

GB0003308607

 

Equity Swap

 

Increasing a long Position

 

2

 

40.86 GBP

GB0003308607

 

Equity Swap

 

Increasing a long Position

 

3

 

40.89 GBP

GB0003308607

 

Equity Swap

 

Reducing a long Position

 

32

 

40.87 GBP

GB0003308607

 

Equity Swap

 

Reducing a long Position

 

912

 

40.86 GBP

GB0003308607

 

Equity Swap

 

Reducing a long Position

 

114

 

40.87 GBP

GB0003308607

 

Equity Swap

 

Increasing a long Position

 

3

 

40.90 GBP

GB0003308607

 

Equity Swap

 

Increasing a long Position

 

389

 

40.88 GBP

GB0003308607

 

Equity Swap

 

Increasing a short Position

 

12

 

40.87 GBP

GB0003308607

 

Equity Swap

 

Reducing a short Position

 

1,136

 

40.88 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

 

Product description e.g. call option

 

Writing, purchasing, selling, varying etc.

 

Number of securities to which option relates

 

Exercise price per unit

 

Type

e.g. American, European etc.

 

Expiry date

 

Option money paid/ received per unit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii) Exercise

Class of relevant security

 

Product description

e.g. call option

 

Exercising/ exercised against

 

Number of securities

 

Exercise price per unit

 

 

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

Class of relevant security

 

Nature of dealing

e.g. subscription, conversion

 

Details

 

Price per unit (if applicable)

 

 

 

 

 

 

 

 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

NONE

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

NONE

 

(c) Attachments

Class of relevant security:

 

5p ordinary (GB0003308607)

 

 

 

Interests

 

Short positions

 

Number

 

%

 

Number

 

%

(1) Relevant securities owned and/or controlled:

 

-

 

-

 

-

 

-

(2) Cash-settled derivatives:

 

 

2,267,061

 

2.281%

 

2,853

 

0.003%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

-

 

-

 

-

-

-

 

TOTAL:

 

2,267,061

 

2.281%

 

2,853

 

0.003%

0

Class of relevant security:

 

5p ordinary (GB0003308607)

 

 

 

Interests

 

Short positions

 

Number

 

%

 

Number

 

%

(1) Relevant securities owned and/or controlled:

 

-

 

-

 

-

 

-

(2) Cash-settled derivatives:

 

 

2,267,061

 

2.281%

 

2,853

 

0.003%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

-

 

-

 

-

-

-

 

TOTAL:

 

2,267,061

 

2.281%

 

2,853

 

0.003%

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at [email protected]. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Millennium Partners, L.P.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Larimar Therapeutics Says Early Data From Friedreich's Ataxia Study Suggest Better Clinical Outcomes
Larimar Therapeutics Says Early Data From Friedreich's Ataxia Study Suggest Better Clinical Outcomes
Dec 16, 2024
09:20 AM EST, 12/16/2024 (MT Newswires) -- Larimar Therapeutics ( LRMR ) said Monday that initial data from its ongoing long-term study of its experimental therapy nomlabofusp in patients with Friedreich's ataxia leaned toward improved clinical outcomes at day 90. The company said patients treated with daily injections of nomlabofusp saw tissue frataxin levels increase, supporting the drug's potential in...
Sinovac Biotech Starts Enrolment in Late-Stage Trial of Investigational Bivalent Vaccine for HFMD
Sinovac Biotech Starts Enrolment in Late-Stage Trial of Investigational Bivalent Vaccine for HFMD
Dec 16, 2024
09:21 AM EST, 12/16/2024 (MT Newswires) -- Sinovac Biotech ( SVA ) said Monday that it has begun enrollment in a late-stage study of its investigational bivalent vaccine targeting Hand, Foot, and Mouth Disease, or HFMD, caused by enterovirus 71 and coxsackievirus 16. The company said the trial will evaluate the potential vaccine's efficacy, safety, and immune response in children...
Shyft to Merge With Aebi Schmidt in All-Stock Deal
Shyft to Merge With Aebi Schmidt in All-Stock Deal
Dec 16, 2024
09:25 AM EST, 12/16/2024 (MT Newswires) -- Shyft ( SHYF ) and Aebi Schmidt said Monday they have agreed to merge in an all-stock deal to create a specialty vehicles company. Under the deal, each outstanding Shyft ( SHYF ) share will be exchanged for 1.04 shares of the combined company's shares, the companies said, adding that Shyft ( SHYF...
GSK's Jemperli Recommended for Expanded Approval in Endometrial Cancer, Receives Breakthrough Therapy Designation for Rectal Cancer
GSK's Jemperli Recommended for Expanded Approval in Endometrial Cancer, Receives Breakthrough Therapy Designation for Rectal Cancer
Dec 16, 2024
09:21 AM EST, 12/16/2024 (MT Newswires) -- GSK (GSK) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the approval of its experimental drug, Jemperli, in combination with chemotherapy, as a first-line treatment for adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. The company said the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved